Workshop VII (KCL, London 2015)  Regulatory challenges of personalised medicine: a transnational perspective
Jun
22
9:00 AM09:00

Workshop VII (KCL, London 2015) Regulatory challenges of personalised medicine: a transnational perspective

The workshop will explore the regulatory challenges of personalised medicine from a transnational perspective, as part of the ESRC project State strategies of governance in global biomedical innovation; the impact of China and India. The focus will be on two critical issues: the challenges associated with rapid technological advances in next generation sequencing, and the changing regulatory status of laboratory-developed tests. The workshop will bring together a variety of experts from government (US FDA, UK MHRA, UK NICE, EU EMA), industry (Illumina, Janssen Diagnostics, NIBSC-UKSCB) and academia (KCL, INCa-France, UCSF-USA) from Europe, North America, India and China.

Invitation only. Email Saheli Datta (saheli.datta@kcl.ac.uk) to register interest. 

View Event →
Workshop VI (Sussex 2015):  Global Biomedical Informatics: Innovation, Governance and Societal Engagement.
Feb
18
9:00 AM09:00

Workshop VI (Sussex 2015): Global Biomedical Informatics: Innovation, Governance and Societal Engagement.

This event was jointly organised by King’s College London and University of Sussex. 

The heralded revolutions in global medicine and healthcare fuelled by the life sciences and genomics require the harnessing of the ever-increasing waves of data that are being generated, through development and deployment of informatics tools, databases and data interpretation. There is a need to better understand the governance and steering of bioinformatics by national governments’ and other governance actors’ on the global stage. Social and scientific trends such as open access and consumerisation underpin developments in the field. This workshop addresses this challenge by bringing together a range of stakeholders from academia, government and commercial bodies. 

Participation in the event was by invitation only. 

View Event →
Workshop/Conference III (New Delhi, 2014):  Biomedical Innovation and the Public
Mar
13
to Mar 14

Workshop/Conference III (New Delhi, 2014): Biomedical Innovation and the Public

Prioritization of Biomedical innovation by developed and developing nations as a key driver of economy under conditions of globalization is a recent phenomenon. Biomedical innovation spans over a wide range of technological platforms like stem cell therapies and tissue engineering under regenerative medicine, genetic engineering, bioinformatics, pharmacogenomics etc. under personalized medicine. The process of biomedical innova-tion, from basic science, through clinical ex-perimentation and clinical trials, to the thera-peutic products and services is characterized by uncertainty. The overlapping of uncer-tainty along with the attempts by countries like India and China to capitalize on these technologies and determine the trajectory of bioeconomy has transformed biomedical in-novation in to a techno-political space with national and international consequences. The dynamics of biomedical innovation space is characterized by state, national firms and ser-vice providers, multinational corporations and civil society organizations competing to deter-mine the emerging governance space of bio-medical innovation.

In this context the Centre for Studies in Science Policy (CSSP), Jawaharlal Nehru University, New Delhi in collaboration with King’s College, London organised a two day workshop to explore the linkages between biomedical innovation and governance with a focus on consumers of biomedical innovation. Addressing the question of the implications of emerging governance space of bio-medical innovation for consumers in different biomedical innovation models? 

The event was attended by a mix of 50 eminent scholars from all over India, policymakers and select industry leaders.

Participation of the event was by invitation only. 

 

View Event →
Oct
31
9:00 AM09:00

Workshop II (Beijing, 2013): The Political Economy of the Global Stem Cell Therapy Market

Innovation in lifesciences in general and stem cell science in particular is driven by interlinked set of global markets with many and various governance arrangement at national and transnational levels. Predominant among these markets are research funding, scientific labour, research materials, clinical labour, venture capital, patenting and, at last but not the least, health consumers. It is the operation of the latter market which, in the case of stem cell science, has provoked controversy across the globe in countries such as South Korea, Thailand, China, India, the US, Japan and Italy as the demand from health consumers for treatment of diseases as diverse as spinal cord injury, neuro degenerative disorders, diabetes mellitus, heart disease and Lyme disease has collided with the capacity of medical scientists to deliver innovative stem cell therapies. Global health consumer demand for stem cell therapies is vibrant but the supply of treatments from the conventional science-based model of innovation is small and unlikely to increase in the near future. At the same time, models of medical innovation have emerged that can respond to the demand, often employing a transnational value chain to deliver the product. Much of the commentary has approached the issue from the supply side perspective, demonstrating the extent to which national and transnational regulation fails to impose what are regarded as appropriate standards on the 'illicit' supply of stem cell therapies.

 In contrast, this workshop was held to discuss the political economic analysis with a strong demand side analysis as presented in the forthcoming paper by Salter, Zhou and Datta (2014). The paper and the presentation in the workshop argued that the problem of what is termed  'stem cell tourism' is embedded in the demand-supply relationship of the health consumer market and its engagement with different types of stem cell therapy innovation and that to be meaningful, discussions of regulation must recognize that analysis or risk being sidelined by a market which ignores their often wishful thinking.

Participation in the event was by invitation only. 

 

View Event →
Mar
15
9:00 AM09:00

Workshop I (London 2013): Global Governance of Human Embryonic Stem Cell Research and Therapy - An Example from India

A policy workshop was held on 15 March 2013 at King’s College London as part of the ESRC funded research ‘State strategies of governance in biomedical innovation: the impact of China and India’. This research project explores emerging innovation dynamics and trans-national governance in the context of the increasing importance of the life sciences and technologies in countries’ and regions’ competitive and collaborative economic strategies, and the recognition that biomedical sciences raise difficult questions of ethics and of social impact. The workshop was a first of a series of workshops, whose results are designed to inform public policy-making in a range of fields in regenerative and personalised medicine in the UK and the ‘Rising Powers’ of India and China.

View Event →